† 2DL2 and 2DL3 also react weakly with HLA-C Lys80 (C2 epitope) and a few HLA-B alleles bearing the C1 epitope (e.g., HLA-B*4601 and HLA-B*7301) [118–120]. HCMV: Human cytomegalovirus; HCV ...

By connecting with its tumor-associated overexpression ligands, such as MICA, MICB, and ULBPs, NKG2D, an activating NK cell receptor can modulate the cytotoxic capability of NK cells against ...

Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell ...

Some recent studies have provided examples of NK cell involvement in allograft tolerance. NK cells possess allele-specific inhibitory receptors that could interact with specific alleles of HLA and ...

Clinical relevance: Receptor engineering has significantly advanced NK cell-based cancer immunotherapies. As technical hurdles are overcome, these innovative treatments are poised to revolutionize ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...

They also proposed a new immunotherapy strategy based on receptor antagonism. Their study was published in Nature Immunology ...

We are interested in further understanding the molecular and cellular mechanisms involved in NK cell development, effector function, and generation of memory. We have recently demonstrated that ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...